These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 5062540)

  • 41. Properties of bovine factor IX (Christmas factor).
    Davie EW; Fujikawa K; Kato H; Legaz ME
    Ann N Y Acad Sci; 1975 Jan; 240():34-42. PubMed ID: 234217
    [No Abstract]   [Full Text] [Related]  

  • 42. Measurement of human activated factor X-antithrombin complex by an enzyme-linked differential-antibody immunosorbent assay.
    Jesty J; Morrison SA; Harpel PC
    Anal Biochem; 1984 May; 139(1):158-67. PubMed ID: 6742427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurement of the kinetics of inhibition of activated coagulation factor X in human plasma: the effect of plasma and inhibitor concentration.
    Jesty J
    Anal Biochem; 1986 Feb; 152(2):402-11. PubMed ID: 2421604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1979 Sep; 586(3):584-93. PubMed ID: 476156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preparation of modified bovine factor VIII with enhanced biological activity using insoluble-trypsin columns.
    Vogel CN; Parfitt HE; Kingdon HS; Lundblad RL
    Thromb Diath Haemorrh; 1973 Nov; 30(2):229-34. PubMed ID: 4773363
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III.
    Scully MF; Kakkar VV
    Biochem J; 1984 Sep; 222(3):571-8. PubMed ID: 6207810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 48. Mechanisms of inhibition of platelet coagulant activity.
    Ellis V; Scully MF; Kakkar VV
    Adv Exp Med Biol; 1985; 192():373-87. PubMed ID: 2422887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.
    Kleanthous S; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chaudry L; Chan C; Clarte MO; Convery MA; Harling JD; Hortense E; Irving WR; Irvine S; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Roethka TJ; Senger S; Shah GP; Stelman GJ; Toomey JR; Watson NS; West RI; Whittaker C; Zhou P; Young RJ
    Bioorg Med Chem Lett; 2010 Jan; 20(2):618-22. PubMed ID: 20006499
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of two distinct heparin cofactors in human plasma. Separation and partial purification.
    Briginshaw GF; Shanberge JN
    Arch Biochem Biophys; 1974 Apr; 161(2):683-90. PubMed ID: 4839055
    [No Abstract]   [Full Text] [Related]  

  • 51. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
    Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
    Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.
    Lockett JM; Mast AE
    Biochemistry; 2002 Apr; 41(15):4989-97. PubMed ID: 11939795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of protein synthesis inhibitors on the vicasol-induced change in the content of the thermostable antifactor Xa in the blood serum].
    Byshevskii ASh; Galian SL
    Vopr Med Khim; 1980; 26(1):85-8. PubMed ID: 6768192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of factor X and factor V activation by dermatan sulfate and a pentasaccharide with high affinity for antithrombin III in human plasma.
    Ofosu FA; Choay J; Anvari N; Smith LM; Blajchman MA
    Eur J Biochem; 1990 Oct; 193(2):485-93. PubMed ID: 2226466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
    Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heparin fractions and derivatives.
    Wehrmacher WH
    Semin Thromb Hemost; 1985 Apr; 11(2):218-21. PubMed ID: 3898372
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.
    Barrowcliffe TW; Havercroft SJ; Kemball-Cook G; Lindahl U
    Biochem J; 1987 Apr; 243(1):31-7. PubMed ID: 3606581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory effect of activated protein C on activation of prothrombin by platelet-bound factor Xa.
    Dahlbäck B; Stenflo J
    Eur J Biochem; 1980 Jun; 107(2):331-5. PubMed ID: 6893181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in serological properties of macroglobulins from cancer and normal sera.
    Oliver-González J; Gadea D
    Proc Soc Exp Biol Med; 1966 Dec; 123(3):802-5. PubMed ID: 5959022
    [No Abstract]   [Full Text] [Related]  

  • 60. Two progressive inhibitors of factor Xa in human blood.
    Marciniak E; Tsukamura S
    Br J Haematol; 1972 Mar; 22(3):341-51. PubMed ID: 5062540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.